E2F1

Across TCGA pan-cancer cohorts, E2F1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated E2F1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher E2F1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated E2F1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, ESCA, and SKCM are the cancer types where E2F1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.133	0.684	.002	18	view →
ESCA	DFS	Median	II,III,IV	0.089	0.522	.001	12	view →
SKCM	OS	Median	II,III,IV	0.174	0.731	<.001	12	view →
UCEC	DFS	Median	All	0.967	0.829	.029	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

E2F1–BLCA (OS)

Open the BLCA breakdown →